Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Should You Invest in the iShares Biotechnology ETF (IBB)?
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
Watch for potential wave of share splits as the average price of S&P 500 stock hits $160, says Strategas
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
US FDA declines to approve Regeneron's blood cancer therapy
UPDATE 1-US FDA declines to approve Regeneron's blood cancer therapy
Regeneron Provides Update on Biologics License Application for Odronextamab
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
Top Research Reports for JPMorgan Chase, Merck & SAP
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
UPDATE 1-US appeals court revives Regeneron's antitrust lawsuit against Novartis
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.